Meridian Wealth Management LLC Increases Holdings in Eli Lilly and Company $LLY

Meridian Wealth Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 10.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,133 shares of the company’s stock after purchasing an additional 1,035 shares during the quarter. Meridian Wealth Management LLC’s holdings in Eli Lilly and Company were worth $8,494,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dash Acquisitions Inc. raised its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares in the last quarter. Nvest Financial LLC lifted its holdings in shares of Eli Lilly and Company by 0.6% in the 2nd quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock worth $1,773,000 after acquiring an additional 13 shares during the last quarter. MPS Loria Financial Planners LLC boosted its position in shares of Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after buying an additional 13 shares during the period. Key Client Fiduciary Advisors LLC boosted its holdings in Eli Lilly and Company by 1.2% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock valued at $867,000 after acquiring an additional 13 shares during the period. Finally, Darwin Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 3.6% during the third quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock valued at $285,000 after purchasing an additional 13 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. HSBC reiterated a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a report on Wednesday, November 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Wednesday, January 14th. Four research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,162.75.

Eli Lilly and Company Stock Up 1.3%

Eli Lilly and Company stock opened at $1,037.84 on Friday. The stock has a market capitalization of $981.15 billion, a PE ratio of 50.77, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The business has a 50 day simple moving average of $1,056.87 and a 200-day simple moving average of $889.48. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the business earned $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO David Ricks said impending Medicare coverage for obesity drugs could “change the game” for the launch of Lilly’s oral obesity candidate orforglipron, signaling a major commercial catalyst if access and reimbursement broaden this year. Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
• Positive Sentiment: Lilly announced a $3.5 billion Lehigh Valley (PA) injectable manufacturing plant to produce next?gen weight?loss drugs (including retatrutide), expanding U.S. capacity and creating ~2,800 jobs — a material long?term supply and growth investment. Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
• Positive Sentiment: TD Cowen raised its price target sharply to $1,250 and maintained a buy rating, providing analyst backing that can support further upside and investor confidence. TD Cowen adjusts price target on Eli Lilly and Co to $1,250
• Positive Sentiment: Lilly expanded its R&D and partnering footprint with a ~ $1.93B deal with Repertoire (autoimmune therapies) and other gene?editing/oncology investments, diversifying future growth drivers beyond GLP?1s. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Neutral Sentiment: Competitor Novo Nordisk ramped U.S. advertising for Wegovy/Ozempic after prior supply constraints eased, outspending Lilly — a sign of intensifying marketing competition in obesity that could pressure share gains or require higher promotional spend. Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases
• Negative Sentiment: The FDA action date for Lilly’s oral weight?loss pill orforglipron was moved to April 10 (Q2), delaying potential revenue contribution and near?term clarity on approval — a timing risk that can cap upside until the new decision date. FDA Decision on Eli Lilly’s Weight Loss Pill Delayed to Q2

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.